RESEARCH

Canadian PH Registry

One of the most exciting and significant efforts undertaken by Canada’s pulmonary hypertension community in the last five years is the Canadian Pulmonary Hypertension Registry (CPHR).

What is the CPHR and why was it started?

The CPHR is a database of patient data collected to help better understand pulmonary hypertension (PH) and improve patient care. Data on the Canadian PH population is lacking, especially for the rarest forms of PH, PAH and CTEPH. This registry allows us to understand PH better and its impacts on patients.

Your participation is essential to the success of CPHR

Your local PH clinic team will have more information about the registry and how to sign up.

Once you are signed up, you will not have to do anything extra. The registry will collect only the relevant data from your medical chart, allowing researchers to use the data collected for future research and quality improvement projects. We can use the data to advocate for more funding and resources in PH patient care. We can also use data to educate and promote awareness of PH.

Your personal information is safe

You will never be identified individually. Your data will be grouped with other data and used in reports, publications, and presentations.

Learn more about the CPHR

Annual Report

CPHR Annual Report - July 2021 to June 2022

What have we learned from the CPHR?

The following academic articles all feature studies conducted using data from the Canadian PH Registry.

Alquraishi H, Swiston JR, Lee L, Legkaia L, Norena M, Alobaidellah K, Kapasi K, Levy RD, Brunner NW.

The Association Between Median Income and Severity of Pulmonary Hypertension at Diagnosis and Risk at Follow Up in a Public Health Care System. ATS 2022.

https://www.abstractsonline.com/pp8/#!/10476/presentation/6476

Brunner NW, Legkaia L, Al-Ahmadi F, Lee L, Norena M, Lam CSM, Yim JJ, Luong C, Weatherald J, Nador RG, Levy RD, Swiston JR.

Does community size or commute time affect the severity of illness at diagnosis or quality of care in a centralized care model of pulmonary hypertension?, Int J Cardiol. 2021 Jun 1;332:175-181.

https://doi.org/10.1016/j.ijcard.2021.03.035

Moghaddam N, Swiston JR, Tsang MYC, Levy R, Lee L, Brunner NW.

Impact of targeted pulmonary arterial hypertension therapy in patients with combined post-and precapillary pulmonary hypertension. Am Heart J. 2021;235:74-81.

https://doi.org/10.1016/j.ahj.2021.01.003

Moghaddam N, Swiston JR, Weatherald J, Mielniczuk L, Kapasi A, Hambly N, Langleben D, Brunner NW.

Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. Int J Cardiol. 2020 May 1;306:181-186.

https://doi.org/10.1016/j.ijcard.2019.11.104

Sugarman J, Weatherald J, ThakrarM, Helmersen D, Hirani N, Varughese R, Liu J.

Pulmonary Artery Pulsatility Index as a Predictor of Mortality in Pulmonary Arterial Hypertension. CHEST, Volume 158, Issue 4, A2235 - A2236.

https://doi.org/10.1016/j.chest.2020.08.1906

Zelt JGE, Sugarman J, Weatherald J, Partridge ACR, Liang J, Swiston J, Brunner B, Chandy G, Stewart DJ, Contreras-Dominguez V, Thakrar M, Helmersen D, Varughese R, Hirani N, Umar F, Dunne R, Doyle-Cox C, Foxall J, Mielniczuk L.

Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS Guideline Era. European Respiratory Journal Jan 2021, 2101552; DOI:

https://doi.org/10.1183/13993003.01552-2021

Brandon Budhram, Emma Spence, Andrea Gardner, Jason Weatherald, John Swiston, Lena Legkaia, Steeve Provencher, Kristina Kemp, George Fox, Julia Foxall, George Chandy, Nathan Hambly.

Transitioning Patients with Pulmonary Arterial Hypertension from Parenteral Prostacyclin Therapy to Oral Selexipag: A Multi-center Retrospective Case-Control Study. American Thoracic Society Conference 2023, Washington, D.C.

https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A6447